Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PDE6D | O43924 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162910 | 0.93 | HMGCR (0.53) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13100382 | 0.90 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3259413 | 0.90 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL15371657 | 0.89 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8239672 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1978780 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2050594 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2050597 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1978779 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7933980 | 0.89 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850213-B2 | Method for preparing rosuvastatin sodium | JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD. (CN) | 2017-12-26 | — | — | US | disclosed |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | FUDAN UNIVERSITY (CN) | 2017-06-29 | — | — | US | disclosed |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2011-12-08 | — | — | US | disclosed |
| US-8063213-B2 | Reacting (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl) acetic acid with hydrochloric acid, salt formation with sodium or potassium hydroxide, basification, desolventization, salt exchange | ASTRAZENECA UK LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20080221323-A1 | Production of Rosuvastatin Calcium Salt | ASTRAZENECA UK LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221323-A1 | Production of Rosuvastatin Calcium Salt | HMGCR, INPP5D, INPPL1 | HMGCR 1/4885ALDH1A1 2489/4885CYP3A4 2136/4885 |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, GRHPR | HMGCR 1/4885ALDH1A1 1706/4885CYP3A4 1086/4885 |
| US-20170183314-A1 | METHOD FOR PREPARING ROSUVASTATIN SODIUM | HMGCR, NOX4, PTEN | HMGCR 1/4885ALDH1A1 1238/4885CYP3A4 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.